C. Escriu

发表

Diverse epigenetic strategies interact to control epidermal differentiation

F. Markowetz, Yoko Ito, P. Pavlidis, 2012, Nature Cell Biology.

Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer.

C. Escriu, J. Field, 2016, Journal of thoracic disease.

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.

C. Escriu, A. Addeo, J. Cave, 2022, International immunopharmacology.

Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom

C. Escriu, J. Lester, E. Hudson, 2021, BMC cancer.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).

N. Girard, C. Escriu, Shin‐Yup Lee, 2021, Lung cancer.

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.

C. Escriu, P. Tomasini, K. Clark-Langone, 2020, NPJ precision oncology.

Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom

C. Escriu, J. Lester, E. Hudson, 2020, BMC cancer.

New Insights into Tubulin Binders

J. Brenton, C. Escriu, 2011 .

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA

M. Tsuboi, Y. Yatabe, S. Dacic, 2021, Future oncology.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer

I. Mills, D. Neal, S. Menon, 2018, Oncogene.

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response

C. Escriu, J. Field, M. Davies, 2019, Lung cancer.

Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis

C. Escriu, P. Madureira, G. Mountzios, 2017, Oncotarget.

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

A. Bergamaschi, F. Baehner, C. Escriu, 2020, npj Precision Oncology.

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

C. Escriu, A. Addeo, J. Cave, 2023, International journal of molecular sciences.

P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA

M. Tsuboi, Y. Yatabe, S. Dacic, 2021 .

Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network

C. Escriu, H. Wong, M. Sallam, 2019, BMC Pulmonary Medicine.

P1.04-24 Digital Core Needle-Biopsy to Assess PD-L1 Expression in Non-Small Cell Lung Cancer: Optimal Sampling and Need for Re-Biopsy

C. Escriu, J. Field, M. Davies, 2018, Journal of Thoracic Oncology.

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

C. Escriu, A. Addeo, J. Cave, 2023, Frontiers in Oncology.

Genomic alterations and the incidence of brain metastases in advanced and metastatic non-small cell lung cancer: a systematic review and meta-analysis.

C. Escriu, R. Zakaria, K. Lee, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.